# Fruquintinib Combined With TAS102 for Advanced Gastric Cancer

> **NCT06102785** · — · RECRUITING · sponsor: **Tianjin Medical University Cancer Institute and Hospital** · enrollment: 30 (estimated)

## Conditions studied

- Gastric Cancer

## Interventions

- **DRUG:** Fruquintinib, TAS102

## Key facts

- **NCT ID:** NCT06102785
- **Lead sponsor:** Tianjin Medical University Cancer Institute and Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2023-11-10
- **Primary completion:** 2026-10-10
- **Final completion:** 2026-10-10
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2023-10-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06102785

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06102785, "Fruquintinib Combined With TAS102 for Advanced Gastric Cancer". Retrieved via AI Analytics 2026-06-07 from https://api.ai-analytics.org/clinical/NCT06102785. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*